Ignite Creation Date:
2024-05-05 @ 11:01 PM
Last Modification Date:
2024-10-26 @ 10:27 AM
Study NCT ID:
NCT01236716
Status:
COMPLETED
Last Update Posted:
2014-08-06
First Post:
2010-11-08
Brief Title:
Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of Lung
Sponsor:
Chinese Society of Lung Cancer
Organization:
Chinese Society of Lung Cancer
Study Overview
Official Title:
A Randomized Phase II Clinical Trial of Nab-Paclitaxel and Carboplatin Compared With Gemcitabine and Carboplatin as First-line Therapy in Advanced Squamous Cell Carcinoma of Lung
Status:
COMPLETED
Status Verified Date:
2014-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
C-TONG1002
Brief Summary:
This trial is to study the efficacy of nab-PC vs GC and evaluate toxicity of nab-PC in advanced squamous cell cancer of lung The correlation between the efficacy of nab-PC and some biomarkers is also to be evaluated
Detailed Description:
Albumin-bound paclitaxelnab-P utilizes the albumin binding proteinssuch as gp60caveolin-1 CAV1 and SPARCsecreted protein acidic and rich in cysteine achieving high intratumoral paclitaxel accumulation It is reported that CAV1 is overexpressed in squamous cell cancerSQC so it is possible that nab-PC is more highly active than GC in SQC of lung
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None